2,4-disubstituted pyrimidines as CDK inhibitors
US10464927B2 · kind B2 · utility
5Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 9, 2018 |
| Grant date | Nov 5, 2019 |
| Priority date | — |
| Expiry date | Oct 9, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a 2,4-disubstituted pyrimidine derivative and the use thereof as a therapeutically effective cyclin-dependent kinase (CDK) inhibitor. In particular, the present disclosure relates to the use of a new 2,4-disubstituted pyrimidine derivatives shown in formula (I) and a pharmaceutical composition thereof as a selective CDK4/6 inhibitor in preventing or treating diseases related to CDK4/6.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.